利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.034 秒)

    Compounds with anti-cancer activity
    1.
    发明授权
    Compounds with anti-cancer activity 有权
    化合物具有抗癌活性

    公开(公告)号：US08415357B2

    公开(公告)日：2013-04-09

    申请号：US12950297

    申请日：2010-11-19

    申请人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    发明人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    IPC分类号： A61K31/497 ,  A61K31/44 ,  A61K31/47

    CPC分类号： A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  C07D207/452 ,  C07D207/50 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D417/12

    摘要： Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

    摘要翻译： 提供了新型取代的唑类二恶英，其杀死细胞，抑制细胞增殖，抑制细胞生长，消除细胞周期G2检查点和/或引起适应G2细胞周期停滞。 提供了制备和使用本发明化合物的方法。 本发明提供取代的唑类二恶英以治疗细胞增殖障碍。 本发明包括使用取代的唑类二聚体来选择性地杀死或抑制癌细胞而无需额外的抗癌治疗。 本发明包括使用细胞周期G2-检查点 - 取代的取代唑类二恶英来选择性地使癌细胞对DNA损伤试剂，治疗和/或其它类型的抗癌试剂敏感。

    Compounds with anti-cancer activity
    2.
    发明授权
    Compounds with anti-cancer activity 有权
    化合物具有抗癌活性

    公开(公告)号：US08084454B2

    公开(公告)日：2011-12-27

    申请号：US12082643

    申请日：2008-04-11

    申请人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    发明人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    IPC分类号： A61K31/497 ,  A61K31/505 ,  A61K31/47 ,  A61K31/44 ,  C07D401/12 ,  C07D239/02 ,  C07D215/46

    CPC分类号： A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  C07D207/452 ,  C07D207/50 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D417/12

    摘要： Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

    摘要翻译： 提供了新型取代的唑类二恶英，其杀死细胞，抑制细胞增殖，抑制细胞生长，消除细胞周期G2检查点和/或引起适应G2细胞周期停滞。 提供了制备和使用本发明化合物的方法。 本发明提供取代的唑类二恶英以治疗细胞增殖障碍。 本发明包括使用取代的唑类二聚体来选择性地杀死或抑制癌细胞而无需额外的抗癌治疗。 本发明包括使用细胞周期G2-检查点 - 取代的取代唑类二恶英来选择性地使癌细胞对DNA损伤试剂，治疗和/或其它类型的抗癌试剂敏感。

    Compounds with anti-cancer activity
    3.
    发明申请
    Compounds with anti-cancer activity 有权
    化合物具有抗癌活性

    公开(公告)号：US20080275057A1

    公开(公告)日：2008-11-06

    申请号：US12082643

    申请日：2008-04-11

    申请人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    发明人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato ,  Sayaka Yamamoto ,  Yoko Hasegawa

    IPC分类号： A61K31/4439 ,  C07D401/12 ,  C07D215/38 ,  A61K31/496 ,  A61P35/00 ,  A61K31/4725 ,  C07D401/14

    CPC分类号： A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  C07D207/452 ,  C07D207/50 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D417/12

    摘要： Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.

    摘要翻译： 提供了新型取代的唑类二恶英，其杀死细胞，抑制细胞增殖，抑制细胞生长，消除细胞周期G2检查点和/或引起适应G2细胞周期停滞。 提供了制备和使用本发明化合物的方法。 本发明提供取代的唑类二恶英以治疗细胞增殖障碍。 本发明包括使用取代的唑类二聚体来选择性地杀死或抑制癌细胞而无需额外的抗癌治疗。 本发明包括使用细胞周期G2-检查点 - 取代的取代唑类二恶英来选择性地使癌细胞对DNA损伤试剂，治疗和/或其它类型的抗癌试剂敏感。

    PEPTIDE COMPOUND AND USE THEREOF
    4.
    发明申请
    PEPTIDE COMPOUND AND USE THEREOF 审中-公开
    肽类化合物及其用途

    公开(公告)号：US20100112089A1

    公开(公告)日：2010-05-06

    申请号：US12465536

    申请日：2009-05-13

    申请人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato

    发明人： Takumi Kawabe ,  Machiyo Ishigaki ,  Takuji Sato

    IPC分类号： A61K38/10 ,  C07K7/00 ,  A61K38/14 ,  A61K33/24 ,  A61P35/00

    CPC分类号： C07K7/06 ,  A61K38/00

    摘要： The present invention provides a method for the prophylaxis or treatment of cancer in a mammal, comprising administering a therapeutically effective amount of CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof to the mammal, wherein CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof is administered simultaneously with or before administration of a nucleic acid damaging agent.

    摘要翻译： 本发明提供了一种预防或治疗哺乳动物癌症的方法，包括向哺乳动物施用治疗有效量的CBP501，其前药或其药学上可接受的盐，其中CBP501，其前药或药学上可接受的盐 其与核酸损伤剂的给药同时或之前施用。

    Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments
    5.
    发明授权
    Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments 失效
    消除DNA损伤诱导的细胞周期G2检查点和/或增加DNA损伤治疗的抗癌活性的化合物

    公开(公告)号：US07030111B2

    公开(公告)日：2006-04-18

    申请号：US10457029

    申请日：2003-06-06

    申请人： Takumi Kawabe ,  Hidetaka Kobayashi

    发明人： Takumi Kawabe ,  Hidetaka Kobayashi

    IPC分类号： A61K31/5375 ,  A61K31/495 ,  C07D265/30 ,  C07D241/04

    CPC分类号： C07C327/26 ,  C07C69/76 ,  C07C327/36 ,  C07D213/65 ,  G01N33/5011

    摘要： The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

    摘要翻译： 本发明提供抑制哺乳动物细胞（包括人细胞）中的细胞周期G2检查点，特别是DNA损伤诱导的G2检查点的组合物和方法。 具体地，本发明提供了通过废除细胞周期G2检查点来使细胞对DNA损伤剂敏感的组合物和方法。 本发明的化合物用于治疗增殖性疾病如癌症。 本发明提供了选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗敏感的组合物和方法。

    Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments
    6.
    发明授权
    Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments 失效
    消除DNA损伤的化合物诱导细胞周期G2检查点和/或增加DNA损伤治疗的抗癌活性

    公开(公告)号：US07652042B2

    公开(公告)日：2010-01-26

    申请号：US12131564

    申请日：2008-06-02

    申请人： Takumi Kawabe ,  Hidetaka Kobayashi

    发明人： Takumi Kawabe ,  Hidetaka Kobayashi

    IPC分类号： A61K31/44 ,  A61K31/235 ,  A61K31/095

    CPC分类号： C07C327/26 ,  C07C69/76 ,  C07C327/36 ,  C07D213/65 ,  G01N33/5011

    摘要： The invention provides compositions and methods to inhibit the cell cycle G2 checkpoint, in particular the DNA-damage-induced G2 checkpoint, in mammalian cells including human cells. Specifically, the invention provides compositions and methods to sensitize cells to DNA-damaging agents by abrogating the cell cycle G2 checkpoint. Compounds of the invention are used to treat proliferative disorders such as cancer. The invention provides compositions and methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA-damaging agents and treatments.

    摘要翻译： 本发明提供抑制哺乳动物细胞（包括人细胞）中的细胞周期G2检查点，特别是DNA损伤诱导的G2检查点的组合物和方法。 具体地，本发明提供了通过废除细胞周期G2检查点来使细胞对DNA损伤剂敏感的组合物和方法。 本发明的化合物用于治疗增殖性疾病如癌症。 本发明提供了选择性地使G1检查点受损的癌细胞对DNA损伤剂和治疗敏感的组合物和方法。

    PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY
    7.
    发明申请
    PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY 审中-公开
    具有免疫调节，抗炎和抗病毒活性的肽和肽

    公开(公告)号：US20090192090A1

    公开(公告)日：2009-07-30

    申请号：US12347683

    申请日：2008-12-31

    申请人： Takumi Kawabe ,  Hidetaka Kobayashi

    发明人： Takumi Kawabe ,  Hidetaka Kobayashi

    IPC分类号： A61K38/10 ,  A61K38/08

    CPC分类号： G01N33/5047 ,  A61K38/10 ,  C07K1/1077 ,  C07K14/4705 ,  G01N33/5008 ,  G01N2800/52

    摘要： The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune disorder or inflammation or viral infection by administering an amount of a G2-checkpoint-abrogating peptide or peptidomimetic sufficient to inhibit the disease.

    摘要翻译： 本发明提供具有免疫调节和/或抗炎和/或抗病毒活性的化合物，其中本发明化合物包括肽和肽模拟物。 本发明还提供使用本发明的免疫调节和/或抗炎和/或抗病毒化合物的方法。 特别地，本发明提供了通过给予一定数量的足以抑制该疾病的消除G2检查点的肽或肽模拟物来治疗与免疫疾病或炎症或病毒感染有关的疾病的方法。

    Sensitivity test to predict efficacy of anti-cancer therapies
    9.
    发明申请
    Sensitivity test to predict efficacy of anti-cancer therapies 有权
    敏感性检测预测抗癌疗法的疗效

    公开(公告)号：US20060014157A1

    公开(公告)日：2006-01-19

    申请号：US10913711

    申请日：2004-08-06

    申请人： Takumi Kawabe ,  Hidetaka Kobayashi

    发明人： Takumi Kawabe ,  Hidetaka Kobayashi

    IPC分类号： C12Q1/68 ,  G01N33/574

    CPC分类号： G01N33/5011 ,  A61K31/4745 ,  A61K33/24 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/142 ,  G01N33/502 ,  G01N2800/52 ,  A61K2300/00

    摘要： The present disclosure provides methods for determining the sensitivity of cancerous cells to various anti-cancer therapies and predicting the efficacy of these therapies. Specifically, the present disclosure provides methods for predicting the efficacy of one or more candidate anti-cancer therapies in a patient, based on determining the sensitivity of the patient's cancerous cells after exposure to candidate anti-cancer therapies in vitro. The disclosure further provides methods for predicting the efficacy of candidate anti-cancer therapies by using an in vitro sensitivity test of the patient's cancerous cells and a surrogate in vivo efficacy test of the patient's cancerous cells grafted into a surrogate host. The disclosure further provides methods for selecting the most efficacious anti-cancer therapy(s) for a patient, thereby avoiding ineffective or unnecessary treatments.

    摘要翻译： 本公开提供了确定癌细胞对各种抗癌疗法的敏感性并预测这些疗法的功效的方法。 具体地，本公开提供了基于在体外暴露于候选抗癌疗法之后确定患者癌细胞的敏感性来预测患者中一种或多种候选抗癌疗法的功效的方法。 本公开进一步提供了通过使用患者癌细胞的体外敏感性试验和接种到替代宿主中的患者的癌细胞的替代体内功效试验来预测候选抗癌疗法的功效的方法。 本公开还提供了选择用于患者的最有效的抗癌疗法的方法，从而避免无效或不必要的治疗。